Skip to main content

Table 3 Association of treatment with progression-free survival (PFS)

From: Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients

 

Univariate Analysis

Multivariate Analysis

P a

HR (95% C.I.)

Pb

Treatment

   

 Chemotherapy vs. chemotherapy + bevacizumab

0.890

0.734 (0.325–1.656)

0.457

Gender

   

 Male vs. female

0.344

0.998 (0.262–3.803)

0.998

Smoking status

   

 Smoking vs. non-smoking

0.379

0.646 (0.201–2.077)

0.463

Stage

   

 IV vs. IIIB

0.059

0.265 (0.061–1.150)

0.076

VeriStrat

   

 Good vs. poor

< 0.001

0.214 (0.088–0.522)

0.011

  1. HR hazard ratio, CI, confidence interval
  2. aP-value was estimated by univariate analysis
  3. bHR, 95% C.I. and P-value were estimated in Cox proportional hazards model
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us